Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prognosis in antiphospholipid syndrome.

M C Amigo1

  • 1Department of Rheumatology, Instituto Nacional de Cardiología Ignacio Chávez, Universidad Nacional Autónoma de México, Mexico City, Mexico. mary_carmenamigo@hotmail.com

Rheumatic Diseases Clinics of North America
|September 6, 2001
PubMed
Summary

Antiphospholipid Syndrome (APS) significantly impacts long-term survival, causing irreversible organ damage and morbidity. Quantifying this damage is crucial for assessing prognosis and treatment effectiveness in APS patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

miR-19b-3p and miR-20a-5p are associated with the levels of antiphospholipid antibodies in patients with antiphospholipid syndrome.

Rheumatology international·2021
Same author

Organ Damage and Quality of Life in Antiphospholipid Syndrome.

Current rheumatology reports·2016
Same author

Lupus in Latin-American patients: lessons from the GLADEL cohort.

Lupus·2015
Same author

[Sleep and women].

Revista de neurologia·2009
Same author

The dysautonomia of fibromyalgia may simulate lupus.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
Same author

Myocardial perfusion defects in patients with autoimmune diseases: a prospective study. Analysis of two diagnostic tests.

Lupus·2006

Area of Science:

  • Rheumatology and Immunology
  • Clinical Medicine
  • Vascular Medicine

Background:

  • Antiphospholipid Syndrome (APS) is associated with significant long-term survival challenges.
  • Thrombosis in APS leads to cumulative, irreversible organ damage and morbidity.
  • Accurate assessment of damage is essential for prognosis and treatment planning in APS.

Purpose of the Study:

  • To highlight the importance of quantifying organ damage in Antiphospholipid Syndrome (APS).
  • To introduce the Antiphospholipid Damage Index (APDI) as a tool for assessing APS-related damage.
  • To emphasize the poor prognosis associated with both primary and secondary APS.

Main Methods:

  • Analysis of prospective large cohort studies in patients with various clinical subsets of APS.

Related Experiment Videos

  • Validation of a newly created Antiphospholipid Damage Index (APDI).
  • Ongoing improvements and refinement of the APDI.

    • Main Results:

    • Large cohort studies confirm a significant negative impact of APS on long-term survival.
    • Evidence shows cumulative, irreversible damage from thrombosis causes organ dysfunction and morbidity.
    • The developed Antiphospholipid Damage Index (APDI) has been validated.

    Conclusions:

    • Antiphospholipid Syndrome (APS), whether primary or secondary, is associated with a poor prognosis.
    • Quantifying cumulative damage is imperative for managing APS prognosis and treatment.
    • The Antiphospholipid Damage Index (APDI) serves as a vital tool for damage assessment in APS.